Get started
Work

96P Lung cancer in patients with a history of allogeneic hematopoietic cell transplantation: A retrospective cohort study with a focus on effectiveness and safety of immune checkpoint inhibitors

Year: 2026
Type: article
Study design: Observational Study
Abstract: Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative treatment for various hematologic conditions. As outcomes of HCT recipients have improved markedly over the past decades, secondary malignancies become a more relevant issue. In many solid tumors, including lung cancer (LC), immune checkpoint inhibitors (ICIs) can provide long-term disease control or even cure in some patients (pts). However, data on ICI efficacy in a post-HCT setting is limited, and the risk of graft-vs-host disease (GvHD) raises serious concerns about their use.
Source: ESMO Open
DOI: 10.1016/j.esmoop.2026.106403
Authors: F. Acker, C. Wehr, M. Kemper, A. Brauss, F. Stölzel, J. Frietsch, F. Lennartz, N. Steiner, M. Janning, N. Frost, L. Claas, M. Reck, J. Rogado, A. Tufman, B.K. Sobocki, I.R. Reid, F. Herster, M. Sebastian, G. Bug, M. Rost
Institutions: Goethe University Frankfurt, University Hospital Frankfurt, University of Freiburg, University Medical Center Freiburg, University Hospital Münster, University of Göttingen, University Hospital Schleswig-Holstein, Universitätsklinikum Würzburg, Medizinische Hochschule Hannover, Innsbruck Medical University, Universität Innsbruck, University Medical Centre Mannheim, Charité - Universitätsmedizin Berlin, University Hospital Bonn, German Center for Lung Research, LungenClinic Grosshansdorf, Hospital Universitario de La Princesa, LMU Klinikum, Ludwig-Maximilians-Universität München, Gdańsk Medical University, University College Hospital, University College London, Robert Bosch Hospital
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,910
OpenAlex ID: W7137944488
FWCI:
Cites:
Cited by:
Related to: